H.C. Wainwright launched coverage of Arcturus Therapeutics (NASDAQ:ARCT) with a “buy” rating and $15 price target. The stock closed at $7.91 on April 4. Arcturus is focused on the development of novel messenger RNA...

Roth Capital Partners raised its price target for Recro Pharma (NASDAQ:REPH) to $10 from $7.50 but maintained a “neutral” rating, pending greater understanding of the company’s contract development and manufacturing...

BTIG upgraded iRhythm Technologies (NASDAQ:IRTC) to “buy” with an $80 price target, citing a drastic pullback in the stock that “opens a window of opportunity.” The stock closed at $69.34 on April 2. “For a long time...

BTIG upgraded AtriCure (NASDAQ:ATRC) to “buy” from “neutral” with a price target of $35 based on the shares having recently slid. The stock closed at $27.37 on April 1. At a current 3.8 times enterprise value/next 12...

Ladenburg Thalmann raised its price target for TG Therapeutics (NASDAQ:TGTX) to $39 from $27 after the company presented positive interim data from a Phase 2b pivotal trial in relapsed/refractory marginal zone lymphoma...

Canaccord Genuity initiated coverage of ShockWave Medical (NASDAQ:SWAV) with a “buy” rating and $39 price target. The stock closed at $33.47 on March 29. Analyst Jason Mills writes that ShockWave’s technology –...

Maxim Group downgraded Proteon Therapeutics (NASDAQ:PRTO) to “hold” from “buy” and withdrew its previous $5 price target after the company’s second Phase 3 study of vonapanitase failed to reach statistical significance...

EyePoint Pharmaceuticals (NASDAQ:EYPT) priced a public offering of 10,526,500 of its common shares at a price of $1.90 each to raise about $20-million. EyePoint also granted underwriters a 30-day option to purchase up...

SVB Leerink launched coverage of Fate Therapeutics (NASDAQ:FATE) with an “outperform” rating and $20 price target. The stock closed at $16.71 on March 27. Analyst Daina Graybosch writes that Fate is at the forefront of...

SVB Leerink initiated coverage of Affimed NV (NASDAQ:AFMD) with an “outperform” rating and $8 price target. The stock closed at $4.17 on March 27. “Our positive view is fuelled by the potential of the company’s novel...

Maxim Group raised its price target for Atossa Genetics (NASDAQ:ATOS) to $9 from $5 after the Institutional Review Board approved the use of oral endoxifen as a post-mastectomy treatment in pre-menopausal, estrogen...

Roth Capital Partners downgraded Conatus Pharmaceuticals (NASDAQ:CNAT) to “neutral” with a price target of $1.70 after the company’s ENCORE-NF trial failed to meet its primary endpoint of an improvement of fibrosis...

Roth Capital Partners downgraded Recro Pharma (NASDAQ:REPH) to “neutral” with a price target of $7.50 after the company received a second complete response letter (CRL) from the FDA about its NDA for meloxicam, an...

Canaccord Genuity raised its price target for Nevro (NYSE:NVRO) to $62 from $46 after the medical device maker appointed Keith Grossman as president and CEO, effective immediately. The stock closed at $44.77 on March 19...

Analysts for William Blair and Roth Capital Partners downgraded Restoration Robotics (NASDAQ:HAIR) after the company said it is merging with closely-held Venus Concept. The stock was quoted at 81 cents, down 9 cents, at...

BTIG launched coverage of Momenta Pharmaceuticals (NASDAQ:MNTA) with a “neutral” rating. The stock closed at $14.15 on March 15. Analyst Thomas Schrader writes that Momenta’s transition from a generics company to a more...

Roth Capital Partners initiated coverage of InMed Pharmaceuticals (TSX:IN; OTCQX:IMLFF) with a “buy” rating and 12-month price target of $1.10. The stock closed at 57 cents on March 15. InMed is focused on developing...

BTIG initiated coverage of Arcus Biosciences (NYSE:RCUS) with a “buy” rating and $20 price target. The stock closed at $11.67 on March 15. Arcus is focused on driving antitumor immune responses beyond the level...

BTIG launched coverage of Fluidigm (NASDAQ:FLDM) with a “buy” rating and price target of $15. The stock closed at $12.79 on March 13. Analyst Sung Ji Nam writes that the long-term growth or market potential for the...

Canaccord Genuity raised its price target for Vapotherm (NYSE:VAPO) to $27 from $22 after the company’s fourth quarter results beat expectations. The stock closed at $19.85 on March 12. The company, which develops non...

BTIG raised its price target for Senseonics (NYSE American:SENS) to $4 from $3, saying the company’s new Patient Access Bridge program makes strategic sense, even though it caused Senseonics to lower its 2019 guidance...